Twagirumugabe Theogene, Swaibu Gatare, Walker Timothy David, Lindh Magnus, Gahutu Jean Bosco, Bergström Tomas, Norder Heléne
Department of Microbiology & Clinical Virology, Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg, Guldhedsgatan 10B, 41346, Gothenburg, Sweden.
School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.
BMC Infect Dis. 2017 Jan 6;17(1):32. doi: 10.1186/s12879-016-2149-z.
Rwanda is a central African country with about 12 million inhabitants. The 1994 genocide against the Tutsi destroyed much of the infrastructure, including the health system. Although this has improved significantly, many challenges remain to be addressed. In this study, the prevalence of serological markers of past and ongoing hepatitis B virus (HBV) infection and HBV vaccine related immunity was investigated in samples from blood donors from all regions of Rwanda.
The results from hepatitis B surface antigen (HBsAg) analyses of all (45,061) blood donations collected countrywide in 2014 from 13,637 first time and 31,424 repeat blood donors were compiled. Samples from 581 HBsAg negative blood donors were selected for further analysis for antibodies against HBV, anti-HBs and anti-HBc. Additional 139 samples from HBsAg positive donors were analyzed for HBeAg/anti-HBe (132 samples) and for HBV DNA. The S-gene was amplified by PCR, products sequenced, and phylogenetic analysis was performed.
HBsAg was found in 4.1% of first time donors with somewhat higher prevalence among those from the Central and Eastern regions than from other parts of the country. Indications of past infection was found in 21% of the HBsAg negative donors, 4.3% had only anti-HBs suggesting HBV vaccination. HBeAg was detected in 28 (21%), anti-HBe in 97 (73%), and both HBeAg and anti-HBe in 4 of 132 HBsAg positive donors. HBV DNA was found in 85 samples, and the complete S-gene was sequenced in 58 of those. Phylogenetic analysis of the sequences revealed that all HBV strains belonged to subgenotype A1, and formed one clade in the phylogenetic tree. In addition, 12 strains from first time donors had a unique 18 amino acid deletion in the N-terminal part of the pre-S2 region.
This study indicated that the prevalence of hepatitis B is intermediate in Rwanda and that the vaccination coverage is relatively low in young adults. All surveyed Rwandan blood donors were infected with similar subgenotype A1 strains, and a high frequency of those with anti-HBe had detectable HBV DNA. Several strains had in addition a unique pre-S2 deletion, the virulence of which needs to be further studied.
卢旺达是一个拥有约1200万人口的中非国家。1994年针对图西族的种族灭绝摧毁了包括卫生系统在内的许多基础设施。尽管情况已显著改善,但仍有许多挑战有待解决。在本研究中,对来自卢旺达所有地区的献血者样本中既往和正在进行的乙型肝炎病毒(HBV)感染的血清学标志物以及与HBV疫苗相关的免疫力的流行情况进行了调查。
汇总了2014年在全国范围内收集的所有(45,061份)献血样本的乙型肝炎表面抗原(HBsAg)分析结果,这些样本来自13,637名首次献血者和31,424名重复献血者。从581名HBsAg阴性献血者的样本中选取进行进一步分析,检测抗HBV抗体、抗-HBs和抗-HBc。另外从HBsAg阳性献血者中选取139份样本分析HBeAg/抗-HBe(132份样本)以及HBV DNA。通过PCR扩增S基因,对产物进行测序,并进行系统发育分析。
在4.1%的首次献血者中检测到HBsAg,中部和东部地区献血者中的患病率略高于该国其他地区。在21%的HBsAg阴性献血者中发现既往感染迹象,4.3%的人仅检测到抗-HBs,提示曾接种HBV疫苗。在132名HBsAg阳性献血者中,28名(21%)检测到HBeAg,97名(73%)检测到抗-HBe,4名同时检测到HBeAg和抗-HBe。在85份样本中检测到HBV DNA,其中58份对完整的S基因进行了测序。对序列的系统发育分析表明,所有HBV毒株均属于A1亚基因型,在系统发育树中形成一个分支。此外,12株来自首次献血者的毒株在pre-S2区域的N端部分有一个独特的18个氨基酸的缺失。
本研究表明,卢旺达乙型肝炎的患病率处于中等水平,且年轻人中的疫苗接种覆盖率相对较低。所有接受调查的卢旺达献血者均感染了相似的A1亚基因型毒株,且抗-HBe阳性者中HBV DNA检测阳性的频率较高。此外,几种毒株有独特的pre-S2缺失,其毒力有待进一步研究。